Audit of Hypersensitivity Reactions (HSRs) of Patients with Breast Cancer being Treated with Nab-paclitaxel after Severe HSR to Prior Taxane Chemotherapy; is it Safe?

Purpose: Taxanes (docetaxel and paclitaxel) are standard systemic therapies in treating breast and other cancers. Hypersensitivity reactions (HSRs) are reported in about 10% of patients treated with paclitaxel, with severe reactions in 2 –5%, even with pre-medication [1]. There is also up to 90% cross-reactivity between paclitaxel and docetaxel, for patients who experience a HSR [2]. Nanoparticle albumin-bound (nab-)paclitaxel was initially developed with the aim of reducing toxicity [3]. Early clinical trials of nab-paclitaxel re ported lower rates of HSRs [4], but no published data could be found, other than case reports, reporting the safety of nab-paclitaxel after severe HSR to taxane chemotherapy, despite this practice being routinely adopted in many centres.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research